CD274 and endometrial cancer: Therefore, in this systematic review and meta-analysis of randomized clinical trials (RCTs), our aim is to investigate and clarify the potential benefits in terms of PFS, OS, and safety when utilizing PD-1/PD-L1 inhibitors in combination with carboplatin and paclitaxel chemotherapy, as compared to using carboplatin plus paclitaxel chemotherapy alone, in patients with advanced or recurrent endometrial cancer.